# EDGAR Filing Document

**Accession Number:** 0002077033
**File Stem:** 0000000000-25-008877
**Filing Date:** 2025-8
**Character Count:** 10843
**Document Hash:** d8533f451cd768bf362f047ed928824e
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000000000-25-008877.hdr.sgml**: 20260325

**ACCESSION NUMBER**: 0000000000-25-008877

**CONFORMED SUBMISSION TYPE**: UPLOAD

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20250820

**FILED FOR**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Miluna Acquisition Corp
- **CENTRAL INDEX KEY:** 0002077033
- **STANDARD INDUSTRIAL CLASSIFICATION:** BLANK CHECKS [6770]
- **ORGANIZATION NAME:** 05 Real Estate & Construction
- **EIN:** 000000000
- **STATE OF INCORPORATION:** E9
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** UPLOAD
- **SEC FILE NUMBER:** 377-08262

**BUSINESS ADDRESS:**
- **STREET 1:** 10 E. 53RD STREET, SUITE 3001
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10022
- **BUSINESS PHONE:** 86 18721047071

**MAIL ADDRESS:**
- **STREET 1:** 10 E. 53RD STREET, SUITE 3001
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10022
**PUBLIC REFERENCE ACCESSION NUMBER**: 0001641172-25-021059

## Text-Extract

```

                                                            August 20, 2025

Shang Ju Lin
Chief Executive Officer
Miluna Acquisition Corp
12F, No. 43, Sec. 4
Cheng Kong Road
Taipei, Taiwan

       Re: Miluna Acquisition Corp
           Draft Registration Statement on Form S-1
           Submitted July 25, 2025
           CIK No. 0002077033
Dear Shang Ju Lin:

       We have reviewed your draft registration statement and have the
following comments.

        Please respond to this letter by providing the requested information
and either
submitting an amended draft registration statement or publicly filing your
registration
statement and non-public draft submission on EDGAR. If you do not believe a
comment
applies to your facts and circumstances or do not believe an amendment is
appropriate, please
tell us why in your response.

      After reviewing the information you provide in response to this letter
and your
amended draft registration statement or filed registration statement, we may
have additional
comments.

Draft Registration Statement on Form S-1
Cover Page

1.     We note your intention to apply to have your units listed on the Nasdaq,
and that you
       cannot guarantee that your securities will be approved for listing.
Please clarify
       whether this offering is contingent upon receiving Nasdaq listing
approval.

2.     We note that after completion of this offering and prior to the
consummation of a
       business combination, only holders of your Class B ordinary shares will
have the right
       to vote on the appointment or removal of directors. Please revise here
and elsewhere
       throughout wherever appropriate to disclose whether Nasdaq will consider
you to be a
          controlled company    within the meaning of Nasdaq corporate
governance standards,
 August 20, 2025
Page 2

       or otherwise advise. If so, disclose whether you plan to rely on any
exemptions from
       corporate governance listing requirements as a    controlled company."
3.     Please revise the cover page to clarify, as you have elsewhere, that
subsequent to the
       purchase by MilunaC Technology Limited ("Sponsor") of 1,725,000 insider
shares on
       June 30, 2025, Sponsor transferred an aggregate of 80,000 insider shares
among your
       Chief Executive Officer, Chief Financial Officer and your three
independent directors
       on July 10, 2025 pursuant to executed share transfer agreements.
Additionally, please
       make conforming revisions to footnote (3) of the beneficial ownership
table appearing
       on page 150.
4.     With reference to your disclosure on pages 4 and 110, please revise the
cover page to
       disclose that your sponsor has engaged ARC Group Limited to provide
financial
       advisory services in connection with this offering. Further in this
regard, disclose:
           The amount of any compensation received or to be received by the
advisor, and
           whether such compensation may result in material dilution of the
purchasers'
           equity interests. Provide a cross-reference, highlighted by
prominent type or in
           another manner, to the locations of related disclosures in the
prospectus. Refer to
           Item 1602a)(3) of Regulation S-K.
           State whether there may be actual or potential material conflicts of
interest
           between the advisor and purchasers in the offering. Provide a
cross-reference,
           highlighted by prominent type or in another manner, to the locations
of related
           disclosures in the prospectus. Refer to Item 1602(a)(5) of
Regulation S-K.
5.     Please expand your disclosure indicating that you intend to focus on
business
       combination opportunities where you believe the expertise of your
management team
       and directors will provide a distinct competitive advantage to describe
the industries
       or types of opportunities where you expect your team to have a
competitive
       advantage.
Prospectus Summary
General, page 3

6.     Please revise revise here to state, as you do elsewhere, that LBKX has
not yet
       identified a target for a potential business combination.
Prospectus Summary
Competitive Advantage, page 4

7.     Please expand the last sentence of this section to also disclose, if
true, that competition
       may also impact the attractiveness of the acquisition terms that you are
able to
       negotiate with potential targets.
Our Sponsor, Officers and Directors, page 5

8.     You state that your Chief Executive Officer, Mr. Shang Ju Lin, is the
sole shareholder
       and director of your sponsor and has the sole voting and dispositive
power of the
       shares held by the sponsor. Please also disclose the amount of Mr. Lin's
interest as
       required by Item 1603(a)(7) of Regulation S-K.
 August 20, 2025
Page 3
Securities Ownership and Compensation, page 8

9.     Please revise here, in the similar section on page 114, and elsewhere
throughout
       where appropriate as follows:
           Disclose the financial advisory services provided or to be provided
by ARC
           Group Limited, including any compensation or advisory fees for such
           services. Refer to Item 1602(b)(6) of Regulation S-K.
           Describe the extent to which the private placement warrants
underlying the
           private placement units, which you state on page 165 may be
exercised on a
           cashless basis, may result in a material dilution of the purchasers'
equity interests.
           Refer to Items 1602(b)(6) and 1603(a)(6) of Regulation S-K.
Conflicts of Interest, page 12

10.    Please revise here, in the similar section on page 119, and elsewhere as
appropriate to
       disclose any actual or potential material conflicts of interest between
the financial
       advisor and purchasers in the offering, including those that may arise
in determining
       whether to pursue a de-SPAC transaction. Refer to Item 1602(b)(7) and
Item 1603(b)
       of Regulation S-K.
Effecting Our Initial Business Combination, page 16

11.    You state that if you anticipate that you may not be able to consummate
an initial
       business combination within 18 months from the closing of this initial
public offering,
       subject to extension up to 21 months by means of three one-month
extensions, you
       will seek shareholder approval to extend the date by which you must
consummate
       an initial business combination. Please revise here and throughout
wherever
       appropriate to disclose any limitations on extensions, including the
number of times
       you may extend. Refer to Item (b)(4) of Regulation S-K.
Risk Factors
Our warrant agreement will provide that, subject to applicable law..., page 49

12.    We note that the caption of this risk factor states that any action,
proceeding or claim
       against you arising from the warrant agreement, including under the
Securities Act,
       will be brought in the courts of the State of New York or the United
States District
       Court for the Southern District of New York. This statement seemingly
conflicts with
       the following sentence in the narrative risk factor disclosure: "[t]hese
provisions of the
       warrant agreement will not apply to suits brought to enforce any
liability or duty
       created by the Securities Act or the Exchange Act or any other claim for
which the
       federal district courts of the United States of America are the sole and
exclusive
       forum." Please reconcile or otherwise advise. Additionally, revise this
risk factor to
       state that your exclusive forum provision could increase a warrant
holder's costs to
       bring a claim.
" The nominal purchase price paid by our sponsor...", page 64

13.    You have presented an "implied value" of $7.27 per share upon
consummation of the
       initial business combination compared to an "initial implied value" of
$9.32 per share.
       Please describe and quantify the methods and key assumptions used to
calculate these
 August 20, 2025
Page 4

       amounts, and explain how they relate to corresponding amounts in the
dilution
       presentation on page 98, as applicable.
If we are deemed to be an investment company under the Investment Company
Act..., page
67

14.    Please revise the last sentence of this risk factor describing the
consequences of
       liquidation to investors to also address the impact upon your warrants,
which would
       expire worthless.
Proposed Business
Securities Ownership and Compensation, page 114

15.    We note that both the table appearing at the bottom of page 115 and at
the top of page
       116 have been marked with "(1)" and "(2)," but no related explanatory
footnotes
       appear below the tables. Please revise to include any disclosure
necessary for an
       investor to understand the tables, or otherwise advise. As appropriate,
disclose the
       circumstances under which the sponsor, directly or indirectly, has
transferred or
       could transfer ownership of your securities, or that have resulted or
could result in the
       surrender or cancellation of such securities. Refer to Item 1603(a)(6)
of Regulation S-
       K.
       Please contact Tracie Mariner at 202-551-3744 or Sasha Parikh at
202-551-3627 if
you have questions regarding comments on the financial statements and related
matters. Please contact Lauren Hamill at 303-844-1008 or Suzanne Hayes at
202-551-3675
with any other questions.

                                                             Sincerely,

                                                             Division of
Corporation Finance
                                                             Office of Life
Sciences
cc:   Sally Yin

```

### Attached PDF Documents

**Attachment 1:** `filename1`

_No text found in this document._